Showing posts with label **News ALERTS**. Show all posts
Showing posts with label **News ALERTS**. Show all posts

**URGENT Immediate Action Needed!**

Urgent! Immediate Action Needed!

NYSSMOH strongly urges all members to complete the Community Oncology Alliance (COA) Components of Care Study.

CMS has released the 2010 Medicare Physician Fee Schedule. It contains the 21.5% cut to all physician-related payments. It eliminates consultation codes. And the real surprise is a 6% additional cut to medical oncology.
That’s correct — an additional cut of 6% to medical oncology.

The oncologists own (AMA) data was used by CMS to arrive at these cuts. Every practice should complete and return the Components of Care Survey so we have data to refute this. We need to send out the results of the Components of Care Survey to the Congress, Administration, and the press.

Additionally, this is not a final rule — we have a comment period. In short, we need accurate, realistic data or your practice is facing large cuts next year effective 1/1/10.
The link below will direct you to the COA website.

Components of Care Study

Again, NYSSMOH strongly urges all members to complete the Components of Care Survey and forward this email on to your colleagues.

Providers Beware - Recent Identity Theft Schemes

Protect Your Identity!
If you have recently received a phone call or fax from an alleged contractor employee asking for a “CMS File Update,” please contact the provider enrollment department immediately for verification. If you have responded to an employment opportunity which, in retrospect seems suspicious, again contact the provider enrollment department so the information may be forwarded to the Program Safeguard contractor(PSC). Remember, it takes all of us working together to protect the Medicare Trust Fund.

Common Sense Tips!
1. Perform rigorous research regarding opportunities presented toyou when making application for joint venture opportunities of companies unknown to you.
2. Remove any unnecessary personal identifying information from outgoing correspondence.
3. Do not post your resume on line, especially if it contains any confidential personal identifying information.
4. Remember, no one from Medicare will contact you to verify your Medicare numbers. They already have this information.
5. Don’t leave laptops or other gateways into your personal information unattended.
6. Cancel computer access immediately when anyone leaves your employment.
7. Perform rigorous research regarding the company you intend to work for when applying for employment prior to sharing any personalinformation.
8. Check with your carrier to see what practice locations theyhave listed for you.
9. Contact the OIG Hotline if you suspect you are the victim ofprovider identity theft:

Phone:1-800-HHS-TIPS (1-800-447-8477)
Fax:1-800-223-8164TTY:1-800-377-4950
E-Mail:HHSTips@oig.hhs.gov
Mail:
Office of Inspector GeneralDepartment of Health and Human Services
Attn: HOTLINE
P.O. Box 23489
Washington, DC 20026

Letter to CMS on March 1st Anti-Emetic Policy

On February 22nd NYSSMOH along with UNYSMOH, HOMny and Connecticut Oncology Association sent a letter to CMS on behalf of all members to address the March 1st Anti-Emetic Policy



22 February 2009
Barry M. Straube, MD
Director and Chief Clinical Officer
Office of Clinical Standards and Quality
Centers for Medicare & Medicaid Services
Mail Stop S3-02-01
7500 Security Boulevard
Baltimore, MD 21244

Dear Doctor Straube:
We are writing on behalf of the Connecticut Oncology Association (CtOA), the Hematology Oncology Managers of New York (HOMny), the New York State Society Medical Oncologists & Hematologists (NYSSMOH) and the Upstate New York Society of Medical Oncology Hematology (UNYSMOH) to request that the Centers for Medicare & Medicaid Services and National Government Services (NGS), an A/B Medicare Administrative Contractor, reconsider and rescind the application of limitations on use of injectable medications when an oral equivalent is available in the oncology setting.
While we understand the intent of this policy, the complexity and logistics of cancer care make a blanket application of this policy both contrary to the interests of Medicare patients and to national Medicare policy. It also takes the treatment decision for the individual patient out of the hands of the attending Oncologist.

Background: On January 13, 2009, NGS posted the following announcement on its web site:

Use of Injectable Medications When an Oral Equivalent is Available National Government Services would like to remind providers that the use of injectable medications when an oral form of the same medication is available must meet medical necessity requirements for use of the drug, and for the route of administration. Documentation should indicate that the patient was unable to tolerate the oral preparation prior to initiation of the intravenous form of the medication. An example is a failed course of the oral anti-emetic before starting an intravenous form of the same anti-emetic. Instruction regarding this topic is from the Centers for Medicare & Medicaid Services (CMS) and is a national not a local determination.

References Noted by NGS and CMS: The Medicare Benefit Policy Manual, CMS Publication 100-2, Chapter 15, Section 50.2 & 50.5.4 National Government Services Local Coverage Determination Supplemental Instruction Article for Drugs and Biologicals, Coverage of, for Label and Off-Label Uses - Supplemental Instructions Article (A44930) As noted in the announcement, NGS takes the position that this policy – under which intravenous drugs, including anti-emetics will ordinarily not be covered by Medicare – is mandated by provisions of the Medicare Benefit Policy Manual that were issued in 2005. NGS cites section 50.5.4 of the Manual, but this section does not support its position. This provision relates to Part B coverage of oral antiemetics when they are a “full replacement” for intravenous antiemetics. It provides that, notwithstanding the “full replacement” requirement, Medicare will cover supplemental intravenous antiemetics if the oral antiemetics were ineffective. Section 50.2.A, K of the Manual, also cited by NGS, provides that the route of administration must be medically reasonable and necessary. It states further that “if a drug is available in both oral and injectable forms, the injectable form of the drug must be reasonable and necessary as to using the oral form.” We do not believe that this language was intended to deny coverage to injectable drugs whenever an oral version exists. Instead, we believe that his language is intended to reflect the policy stated in section 50.4.3: Medication given by injection (parenterally) is not covered if standard medical practice indicates that the administration of the medication by mouth (orally) is effective and is an accepted or preferred method of administration for that particular patient. In the case of antiemetics administered in conjunction with anticancer chemotherapy, the standard practice is to use IV antiemetics for moderately and highly emetogenic chemotherapy combinations, although oral antiemetics may sometimes be used instead. In fact, in Section 50.3 of Chapter 15 of the Claims Processing Manual states that the weight of whether or not any drug should be denied by Part B as self-administered is whether ≥ 50% of Medicare beneficiaries are receiving that Medication in a self-administered form. This is not the case with almost all antiemetics and cancer drugs where two forms are available.

Early and effective management of nausea and vomiting is critical to a successful course of treatment. Successful management of these side effects and symptoms caused by the toxic nature of individual and combination therapies has helped patients to tolerate more dose dense treatments and contributed to the decline of cancer death rates. Indeed, the cancer death rate has been steadily declining since the early 1990s. The American Cancer Society reported in February 2008 that death rates from all cancers combined peaked in 1990 for men and 1991 for women. Between1990/1991 and 2004, death rates from cancer decreased 18.4 percent for men and 10.5 percent for women. Coincidentally, during this same time, the treatment and management of cancer has evolved from the hospital setting (predominant before DRGs in 1984) into the physician office setting. By 2001, over 80% of all cancer was being treated in the community physician office setting; in addition the use of IV antiemetics allowed better compliance with the completion of chemotherapy prescribed.

Clarification Needed: The physician’s standard for care in these offices for management of nausea and vomiting is determined not only by whether IV or oral forms of the medications exist, but also is based upon the individual patient’s tolerance for the treatment and management of the side effects, as well as the interactions and composition of all the drugs involved in the treatment. Frequently, failure in management of nausea and vomiting can affect the patient’s health status and state of mind, especially when embarking upon a treatment regimen involving multiple cycles. Clarification is needed by CMS as to whether their intention is to insist upon use of oral when the physician’s judgment and patient history suggest that use of the infusion version of a given drug,. This may mean that therapy will be interrupted due to lack of tolerance by patients, who become dehydrated or have intractable vomiting. This may lead to higher costs to the Medicare program due to the stopping and starting of therapies. The following are just some of the examples where an absolute application of the assumption that a clinically equivalent oral can be readily substituted for an IV version is likely to cause disruption in the care and treatment of Medicare patients, and therefore should justify use of appropriate physician judgment at the time of care delivery. We request clarification of the intent and application of this policy in the following settings:

• Multiple cycles of therapy – if a patient has failed use of an oral on the first line of therapy, they will have already experienced the impact that nausea and vomiting can have on their lives. Common medical practice is to not risk further disruption of care with additional failures, or even the onset of anticipatory nausea and vomiting – a common occurrence for cancer patients, and thus to use IV treatments in subsequent cycles.

• Anticipatory nausea - Shall anticipatory nausea be identified as an appropriate “medically necessary” justification for use of IV antiemetics?

• Complex combination regimens – many chemotherapy regimens constitute multiple complex and highly emetogenic drugs and the preparation for these regimens can also involve multiple supportive care drugs, some of which may have both IV and oral versions. In a vacuum, it is easy to consider the effect and uptake for a single isolated drug. However, chemotherapy is not delivered in a vacuum and many regimens have been built with a standard of care that involves multiple IV versions of a variety of different drugs. The timing and anticipated uptake of the effect of these drugs has been carefully developed and balanced for the most medically effective impact of that regimen.

CMS overstepping authorization – We are concerned that the application of this policy in the cancer disease state may represent a situation where our local MAC is entering both into medical decision-making and attempting to circumvent Medicare law set by Congress by limiting payment for appropriately indicated Part B drugs administered in a physicians office to the least costly alternative. No other MAC has a similar policy, nor have any been drafted that are as sweeping as this one.

A federal court ruling on October 16 has already found that Medicare law does not authorize CMS or the contractors to redefine payment rates or policy that have already been set statutorily. There are several compendia approved by Congress to indicate medically appropriate treatment. Those compendia do not limit use of drugs to one route of administration over another for drugs with both IV and oral forms for very valid reasons, linked to the medical judgment of the physician and each individual patient situation. Even the national oncology guidelines set forth by the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) do not limit use of drugs to one route of administration over another for cancer patients.

Recommendation and request: It is our recommendation that this policy be exempted for drugs involved in the treatment and management of cancer. Our local MAC, NGS, has attempted to create this limitation without regard for the medical complications of such a policy, and without regard for their authority to create limitations for covered items and services as determined by Congress.

Because the appropriate use of drugs is clearly defined through FDA indication as well as the authorized compendia for Medicare coverage, CMS has created a limitation that is inappropriate, particularly in the treatment of cancer. As U.S. District Judge Henry H. Kennedy Jr. wrote in the ruling set forth October 16 from the U.S. District Court for the District of Columbia, “It does not make sense to conclude that Congress, having minutely detailed the reimbursement rates for covered items and services, intended that the secretary could ignore these formulas whenever [he or she] determined that the expense of an item or service was not reasonably necessary…There is no indication that Congress intended to confer such broad authority.”

Respectfully yours,
For the Connecticut Oncology Association:
Steven C. Lattanzi, MD President,
Dawn Holcombe, Executive Director
Tel: 860-305-4510
Email: dawnho@aol.com

For the Hematology Oncology Managers of New York:
Abe Moshel,President
Patricia A. Kaden, Vice President
Tel: 516-921-5533
Email: PatMedOnc@aol.com

For the New York State Society Medical Oncologists & Hematologists
Abe Mittelman,MD, President ,
Tel: 914-681-0025
Email: mittens4@aol.com
Florence Madonia,
Executive Director

For the Upstate New York Society of Medical Oncology Hematology
John Poggi, MD,President
Tel: 315-788-7990
Email: johnpoggi@hotmail.com
Nancy Izzo, Executive Director

Cc: American Society of Clinical Oncology
Community Oncology Alliance
Dr. Paul Deutsch, National Government Services
Nancy Davenport-Ennis, Patient Advocate Foundation

Capitol Hill Project

October 25, 2008

Dear Program Director:

I am writing on behalf of the New York State Society of Medical Oncologists and Hematologists (NYSSMOH), the regional organization representing Heme/Onc specialists in downstate New York. As you may be aware, NYSSMOH extends complementary membership to all Program Directors in our area. A number of Program Directors serve or have served on NYSSMOH's Board of Directors. Complementary associate membership is also extended to second and third year Heme/Onc Fellows in the NYSSMOH area.

The Board of Directors believes that all hematologists/oncologists and their professional societies have an important responsibility to act as advocates for their patients, and to support government funding for Heme/Onc research. We are also exploring strategies to involve younger Heme/Onc physicians in the advocacy and political process. Ideally, such involvement should start during the Fellowship years.

Every March, the American Society of Hematology (ASH) sponsors a Capitol Hill Day. Hematologists/Oncologists come from around the country to meet together in Washington, DC and also to meet with their Senators and Representatives. Their purpose is to lobby for increased Federal funding for Heme/Onc research. They also aim to publicize ASH's commitment to patient care.

NYSSMOH has voted to support and fund a pilot program offering a travel grant to Heme/Onc Fellows in their second or third year to attend ASH's annual Capitol Hill Day as an observer and participant. Travel, lodging and meal expenses would be defrayed for the overnight trip. For 2009, travel grants for 2 Fellows would be provided. NYSSMOH members would also attend and seek appointments with appropriate Senators and Representatives from New York. If the pilot program is successful, NYSSMOH would probably establish it as an annual program for Heme/Onc Fellows. The program might also catch the attention of other state Heme/Onc societies, leading to involvement of their Fellows and members.

The pilot program has been approved by the ASH Committee on Government Affairs. NYSSMOH proposes to offer the opportunity to attend Capitol Hill Day in March, 2009 to all second and third year Fellows in our area by simultaneous email. As per the criteria of ASH's Government Affairs Committee, preference will be given to Fellows who plan to attend the 2008 ASH meeting in San Francisco. There, they will attend the meeting of the Government Affairs Committee and learn about the ASH advocacy goals for 2009. Associate membership in ASH is also expected of the 2 chosen Fellows.

We hope that all Program Directors will support this NYSSMOH project for their Fellows. As soon as possible, PLEASE EMAIL ME louis.reed@nbhn.net the names and email addresses of your second and third year Fellows, so that NYSSMOH may circulate this opportunity to them. Many thanks for your time, interest and support.

Sincerely,

Louis Juden Reed, MDClinical Associate Professor of MedicineAlbert Einstein College of Medicinelouis.reed@nbhn.net

Sumbit your NYSSMOH Capitol Hill Project information on line